Genfit S.A.

GNFT.PA

Biotechnology · Healthcare

Price

€14.42

+0.32 (+2.27%)

Market Cap

€722.2M

Exchange

Euronext Paris

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Dec 31, 2025

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Share count falling — buybacks

−10.4% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 55.6M (2021) → 49.8M (2025)

Winston Score History

The full picture

Genfit is a French biotechnology company that develops medicines for serious liver diseases. Its main focus is on conditions like primary biliary cholangitis (PBC) and other rare liver disorders where the liver becomes damaged over time. The company's lead drug candidate, elafibranor, is being studied as a treatment for PBC, a disease with limited existing options for patients.

Genfit makes money primarily through research partnerships, licensing agreements, and milestone payments from larger pharmaceutical companies rather than selling approved drugs directly to patients. The company is based in Lille, France, and operates mainly in Europe and North America through clinical trials and collaborations. Genfit is still in the development stage, which explains its deeply negative operating margins and high cash burn. The biggest risk the company faces is clinical and regulatory — if its drug candidates fail in late-stage trials or do not receive approval from regulators, the company has no commercial revenue to fall back on.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+233.1% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

-162.1% YoY

YoY Growth Rate

Earnings declining

R&D Spend

€53M/ year

↑ Rising (+12% vs prior year)

80.7% of revenue

4.5x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

11.9%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

€103M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Strong grower

Genfit S.A. is growing revenue at 233% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-56.3%

Thin — -56.3% gross margin

Profit after running costs

Operating Margin

-178.2%

Losing money on operations — -178.2%

Return on the money invested

ROCE

-46.2%

Weak — -46.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-4.5%

Shrinking sales (-4.5% YoY)

Profit growth

EPS YoY

<−1,000%

Earnings shrinking (<−1,000% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-39.2%

Burning cash (-39.2%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial